0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurological Drugs Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-26F14436
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Neurological Drugs Market Research Report 2023
BUY CHAPTERS

Global Neurological Drugs Market Research Report 2025

Code: QYRE-Auto-26F14436
Report
May 2025
Pages:107
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Neurological Drugs Market Size

The global market for Neurological Drugs was valued at US$ 135170 million in the year 2024 and is projected to reach a revised size of US$ 221270 million by 2031, growing at a CAGR of 7.4% during the forecast period.

Neurological Drugs Market

Neurological Drugs Market

Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.
North American market for Neurological Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neurological Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neurological Drugs include Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck, Allergan, GSK, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neurological Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurological Drugs.
The Neurological Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurological Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurological Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Neurological Drugs Market Report

Report Metric Details
Report Name Neurological Drugs Market
Accounted market size in year US$ 135170 million
Forecasted market size in 2031 US$ 221270 million
CAGR 7.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Non-prescription drugs
  • Prescription
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck, Allergan, GSK, Otsuka Pharmaceutical, Takeda, NHU Group, Shionogi, APOTEX, North China Pharmaceutical, Harbin Pharmaceutical Co., Ltd., Lukang Pharmaceutical, Kelun Pharmaceutical, Kehua Biology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neurological Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neurological Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Neurological Drugs Market growing?

Ans: The Neurological Drugs Market witnessing a CAGR of 7.4% during the forecast period 2025-2031.

What is the Neurological Drugs Market size in 2031?

Ans: The Neurological Drugs Market size in 2031 will be US$ 221270 million.

Who are the main players in the Neurological Drugs Market report?

Ans: The main players in the Neurological Drugs Market are Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck, Allergan, GSK, Otsuka Pharmaceutical, Takeda, NHU Group, Shionogi, APOTEX, North China Pharmaceutical, Harbin Pharmaceutical Co., Ltd., Lukang Pharmaceutical, Kelun Pharmaceutical, Kehua Biology

What are the Application segmentation covered in the Neurological Drugs Market report?

Ans: The Applications covered in the Neurological Drugs Market report are Hospital, Clinic

What are the Type segmentation covered in the Neurological Drugs Market report?

Ans: The Types covered in the Neurological Drugs Market report are Non-prescription drugs, Prescription

1 Neurological Drugs Market Overview
1.1 Product Definition
1.2 Neurological Drugs by Type
1.2.1 Global Neurological Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Non-prescription drugs
1.2.3 Prescription
1.3 Neurological Drugs by Application
1.3.1 Global Neurological Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Neurological Drugs Market Size Estimates and Forecasts
1.4.1 Global Neurological Drugs Revenue 2020-2031
1.4.2 Global Neurological Drugs Sales 2020-2031
1.4.3 Global Neurological Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neurological Drugs Market Competition by Manufacturers
2.1 Global Neurological Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neurological Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neurological Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neurological Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neurological Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurological Drugs, Product Type & Application
2.7 Global Key Manufacturers of Neurological Drugs, Date of Enter into This Industry
2.8 Global Neurological Drugs Market Competitive Situation and Trends
2.8.1 Global Neurological Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neurological Drugs Players Market Share by Revenue
2.8.3 Global Neurological Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neurological Drugs Market Scenario by Region
3.1 Global Neurological Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neurological Drugs Sales by Region: 2020-2031
3.2.1 Global Neurological Drugs Sales by Region: 2020-2025
3.2.2 Global Neurological Drugs Sales by Region: 2026-2031
3.3 Global Neurological Drugs Revenue by Region: 2020-2031
3.3.1 Global Neurological Drugs Revenue by Region: 2020-2025
3.3.2 Global Neurological Drugs Revenue by Region: 2026-2031
3.4 North America Neurological Drugs Market Facts & Figures by Country
3.4.1 North America Neurological Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neurological Drugs Sales by Country (2020-2031)
3.4.3 North America Neurological Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neurological Drugs Market Facts & Figures by Country
3.5.1 Europe Neurological Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neurological Drugs Sales by Country (2020-2031)
3.5.3 Europe Neurological Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurological Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Neurological Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neurological Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Neurological Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Neurological Drugs Market Facts & Figures by Country
3.7.1 Latin America Neurological Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neurological Drugs Sales by Country (2020-2031)
3.7.3 Latin America Neurological Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurological Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurological Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neurological Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neurological Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurological Drugs Sales by Type (2020-2031)
4.1.1 Global Neurological Drugs Sales by Type (2020-2025)
4.1.2 Global Neurological Drugs Sales by Type (2026-2031)
4.1.3 Global Neurological Drugs Sales Market Share by Type (2020-2031)
4.2 Global Neurological Drugs Revenue by Type (2020-2031)
4.2.1 Global Neurological Drugs Revenue by Type (2020-2025)
4.2.2 Global Neurological Drugs Revenue by Type (2026-2031)
4.2.3 Global Neurological Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Neurological Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neurological Drugs Sales by Application (2020-2031)
5.1.1 Global Neurological Drugs Sales by Application (2020-2025)
5.1.2 Global Neurological Drugs Sales by Application (2026-2031)
5.1.3 Global Neurological Drugs Sales Market Share by Application (2020-2031)
5.2 Global Neurological Drugs Revenue by Application (2020-2031)
5.2.1 Global Neurological Drugs Revenue by Application (2020-2025)
5.2.2 Global Neurological Drugs Revenue by Application (2026-2031)
5.2.3 Global Neurological Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Neurological Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Neurological Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Company Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Ely Lilly Neurological Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Company Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Actavis Neurological Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Company Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Mylan Neurological Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Company Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Randox Neurological Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Company Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Intellipharmaceutics Neurological Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.7.1 Astrazeneca Company Information
6.7.2 Astrazeneca Description and Business Overview
6.7.3 Astrazeneca Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Astrazeneca Neurological Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Company Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Lundbeck Neurological Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Company Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Allergan Neurological Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Company Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 GSK Neurological Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Company Information
6.11.2 Otsuka Pharmaceutical Description and Business Overview
6.11.3 Otsuka Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Otsuka Pharmaceutical Neurological Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Company Information
6.12.2 Takeda Description and Business Overview
6.12.3 Takeda Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Takeda Neurological Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Company Information
6.13.2 NHU Group Description and Business Overview
6.13.3 NHU Group Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 NHU Group Neurological Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Company Information
6.14.2 Shionogi Description and Business Overview
6.14.3 Shionogi Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Shionogi Neurological Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Company Information
6.15.2 APOTEX Description and Business Overview
6.15.3 APOTEX Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 APOTEX Neurological Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 North China Pharmaceutical
6.16.1 North China Pharmaceutical Company Information
6.16.2 North China Pharmaceutical Description and Business Overview
6.16.3 North China Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 North China Pharmaceutical Neurological Drugs Product Portfolio
6.16.5 North China Pharmaceutical Recent Developments/Updates
6.17 Harbin Pharmaceutical Co., Ltd.
6.17.1 Harbin Pharmaceutical Co., Ltd. Company Information
6.17.2 Harbin Pharmaceutical Co., Ltd. Description and Business Overview
6.17.3 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolio
6.17.5 Harbin Pharmaceutical Co., Ltd. Recent Developments/Updates
6.18 Lukang Pharmaceutical
6.18.1 Lukang Pharmaceutical Company Information
6.18.2 Lukang Pharmaceutical Description and Business Overview
6.18.3 Lukang Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Lukang Pharmaceutical Neurological Drugs Product Portfolio
6.18.5 Lukang Pharmaceutical Recent Developments/Updates
6.19 Kelun Pharmaceutical
6.19.1 Kelun Pharmaceutical Company Information
6.19.2 Kelun Pharmaceutical Description and Business Overview
6.19.3 Kelun Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Kelun Pharmaceutical Neurological Drugs Product Portfolio
6.19.5 Kelun Pharmaceutical Recent Developments/Updates
6.20 Kehua Biology
6.20.1 Kehua Biology Company Information
6.20.2 Kehua Biology Description and Business Overview
6.20.3 Kehua Biology Neurological Drugs Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Kehua Biology Neurological Drugs Product Portfolio
6.20.5 Kehua Biology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurological Drugs Industry Chain Analysis
7.2 Neurological Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurological Drugs Production Mode & Process Analysis
7.4 Neurological Drugs Sales and Marketing
7.4.1 Neurological Drugs Sales Channels
7.4.2 Neurological Drugs Distributors
7.5 Neurological Drugs Customer Analysis
8 Neurological Drugs Market Dynamics
8.1 Neurological Drugs Industry Trends
8.2 Neurological Drugs Market Drivers
8.3 Neurological Drugs Market Challenges
8.4 Neurological Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Neurological Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Neurological Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Neurological Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Neurological Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Neurological Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Neurological Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Neurological Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Neurological Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Neurological Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Neurological Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Neurological Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Neurological Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Neurological Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Neurological Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Neurological Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Neurological Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Neurological Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Neurological Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Neurological Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Neurological Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Neurological Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Neurological Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Neurological Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Neurological Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Neurological Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Neurological Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Neurological Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Neurological Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Neurological Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Neurological Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Neurological Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Neurological Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Neurological Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Neurological Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Neurological Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Neurological Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Neurological Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neurological Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Neurological Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Neurological Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Neurological Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neurological Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Neurological Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Neurological Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Neurological Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Neurological Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Neurological Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Neurological Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Neurological Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Neurological Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Neurological Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Neurological Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Neurological Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Neurological Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Neurological Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Neurological Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Neurological Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Neurological Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Neurological Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Neurological Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Neurological Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Neurological Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Neurological Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Neurological Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Neurological Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Neurological Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Neurological Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Neurological Drugs Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Ely Lilly Company Information
 Table 76. Ely Lilly Description and Business Overview
 Table 77. Ely Lilly Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Ely Lilly Neurological Drugs Product
 Table 79. Ely Lilly Recent Developments/Updates
 Table 80. Actavis Company Information
 Table 81. Actavis Description and Business Overview
 Table 82. Actavis Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Actavis Neurological Drugs Product
 Table 84. Actavis Recent Developments/Updates
 Table 85. Mylan Company Information
 Table 86. Mylan Description and Business Overview
 Table 87. Mylan Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Mylan Neurological Drugs Product
 Table 89. Mylan Recent Developments/Updates
 Table 90. Randox Company Information
 Table 91. Randox Description and Business Overview
 Table 92. Randox Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Randox Neurological Drugs Product
 Table 94. Randox Recent Developments/Updates
 Table 95. Intellipharmaceutics Company Information
 Table 96. Intellipharmaceutics Description and Business Overview
 Table 97. Intellipharmaceutics Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Intellipharmaceutics Neurological Drugs Product
 Table 99. Intellipharmaceutics Recent Developments/Updates
 Table 100. Astrazeneca Company Information
 Table 101. Astrazeneca Description and Business Overview
 Table 102. Astrazeneca Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Astrazeneca Neurological Drugs Product
 Table 104. Astrazeneca Recent Developments/Updates
 Table 105. Lundbeck Company Information
 Table 106. Lundbeck Description and Business Overview
 Table 107. Lundbeck Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Lundbeck Neurological Drugs Product
 Table 109. Lundbeck Recent Developments/Updates
 Table 110. Allergan Company Information
 Table 111. Allergan Description and Business Overview
 Table 112. Allergan Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Allergan Neurological Drugs Product
 Table 114. Allergan Recent Developments/Updates
 Table 115. GSK Company Information
 Table 116. GSK Description and Business Overview
 Table 117. GSK Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. GSK Neurological Drugs Product
 Table 119. GSK Recent Developments/Updates
 Table 120. Otsuka Pharmaceutical Company Information
 Table 121. Otsuka Pharmaceutical Description and Business Overview
 Table 122. Otsuka Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Otsuka Pharmaceutical Neurological Drugs Product
 Table 124. Otsuka Pharmaceutical Recent Developments/Updates
 Table 125. Takeda Company Information
 Table 126. Takeda Description and Business Overview
 Table 127. Takeda Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Takeda Neurological Drugs Product
 Table 129. Takeda Recent Developments/Updates
 Table 130. NHU Group Company Information
 Table 131. NHU Group Description and Business Overview
 Table 132. NHU Group Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. NHU Group Neurological Drugs Product
 Table 134. NHU Group Recent Developments/Updates
 Table 135. Shionogi Company Information
 Table 136. Shionogi Description and Business Overview
 Table 137. Shionogi Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Shionogi Neurological Drugs Product
 Table 139. Shionogi Recent Developments/Updates
 Table 140. APOTEX Company Information
 Table 141. APOTEX Description and Business Overview
 Table 142. APOTEX Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. APOTEX Neurological Drugs Product
 Table 144. APOTEX Recent Developments/Updates
 Table 145. North China Pharmaceutical Company Information
 Table 146. North China Pharmaceutical Description and Business Overview
 Table 147. North China Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. North China Pharmaceutical Neurological Drugs Product
 Table 149. North China Pharmaceutical Recent Developments/Updates
 Table 150. Harbin Pharmaceutical Co., Ltd. Company Information
 Table 151. Harbin Pharmaceutical Co., Ltd. Description and Business Overview
 Table 152. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product
 Table 154. Harbin Pharmaceutical Co., Ltd. Recent Developments/Updates
 Table 155. Lukang Pharmaceutical Company Information
 Table 156. Lukang Pharmaceutical Description and Business Overview
 Table 157. Lukang Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. Lukang Pharmaceutical Neurological Drugs Product
 Table 159. Lukang Pharmaceutical Recent Developments/Updates
 Table 160. Kelun Pharmaceutical Company Information
 Table 161. Kelun Pharmaceutical Description and Business Overview
 Table 162. Kelun Pharmaceutical Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. Kelun Pharmaceutical Neurological Drugs Product
 Table 164. Kelun Pharmaceutical Recent Developments/Updates
 Table 165. Kehua Biology Company Information
 Table 166. Kehua Biology Description and Business Overview
 Table 167. Kehua Biology Neurological Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 168. Kehua Biology Neurological Drugs Product
 Table 169. Kehua Biology Recent Developments/Updates
 Table 170. Key Raw Materials Lists
 Table 171. Raw Materials Key Suppliers Lists
 Table 172. Neurological Drugs Distributors List
 Table 173. Neurological Drugs Customers List
 Table 174. Neurological Drugs Market Trends
 Table 175. Neurological Drugs Market Drivers
 Table 176. Neurological Drugs Market Challenges
 Table 177. Neurological Drugs Market Restraints
 Table 178. Research Programs/Design for This Report
 Table 179. Key Data Information from Secondary Sources
 Table 180. Key Data Information from Primary Sources
 Table 181. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Neurological Drugs
 Figure 2. Global Neurological Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neurological Drugs Market Share by Type: 2024 & 2031
 Figure 4. Non-prescription drugs Product Picture
 Figure 5. Prescription Product Picture
 Figure 6. Global Neurological Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Neurological Drugs Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Global Neurological Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Neurological Drugs Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Neurological Drugs Sales (2020-2031) & (K Units)
 Figure 13. Global Neurological Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 14. Neurological Drugs Report Years Considered
 Figure 15. Neurological Drugs Sales Share by Manufacturers in 2024
 Figure 16. Global Neurological Drugs Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Neurological Drugs Players: Market Share by Revenue in Neurological Drugs in 2024
 Figure 18. Neurological Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Neurological Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Neurological Drugs Sales Market Share by Country (2020-2031)
 Figure 21. North America Neurological Drugs Revenue Market Share by Country (2020-2031)
 Figure 22. United States Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Neurological Drugs Sales Market Share by Country (2020-2031)
 Figure 25. Europe Neurological Drugs Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Neurological Drugs Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Neurological Drugs Revenue Market Share by Region (2020-2031)
 Figure 33. China Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Latin America Neurological Drugs Sales Market Share by Country (2020-2031)
 Figure 41. Latin America Neurological Drugs Revenue Market Share by Country (2020-2031)
 Figure 42. Mexico Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Brazil Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Argentina Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Middle East and Africa Neurological Drugs Sales Market Share by Country (2020-2031)
 Figure 46. Middle East and Africa Neurological Drugs Revenue Market Share by Country (2020-2031)
 Figure 47. Turkey Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. UAE Neurological Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Global Sales Market Share of Neurological Drugs by Type (2020-2031)
 Figure 51. Global Revenue Market Share of Neurological Drugs by Type (2020-2031)
 Figure 52. Global Neurological Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 53. Global Sales Market Share of Neurological Drugs by Application (2020-2031)
 Figure 54. Global Revenue Market Share of Neurological Drugs by Application (2020-2031)
 Figure 55. Global Neurological Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 56. Neurological Drugs Value Chain
 Figure 57. Channels of Distribution (Direct Vs Distribution)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Amyotrophic Lateral Sclerosis Gene Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4R20263
Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Online Speech Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-39V19943
Sat Nov 22 00:00:00 UTC 2025

Add to Cart

Global Nerve Repair and Regeneration Devices Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-10C17235
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Neurological Disease Model Chip Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-7M17348
Thu Nov 06 00:00:00 UTC 2025

Add to Cart